Ryplazim

Risk of bleeding in active mucosal disease-related lesions (eg, GI, hemoptysis, epistaxis, vaginal, hematuria). Other recent history of GI bleed (eg, gastric ulcers). May prolong or worsen bleeding in those with bleeding diatheses; monitor during and for 4hrs after infusion. Risk of tissue sloughing at mucosal sites (eg, respiratory, GI, genitourinary). Confirmed or suspected airway disease; monitor closely. Have trained personnel and support equipment readily available. Monitor at-risk patients for at least 4hrs after first dose. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Discontinue immediately if uncontrolled bleeding or hypersensitivity reactions occur; treat appropriately. Loss of efficacy: monitor and obtain plasminogen activity trough to confirm adequate activity levels achieved. Elevated D-dimer levels may occur; will lack interpretability in screening for venous thromboembolism. Elderly. Pregnancy. Nursing mothers.